Accord Logo

Intended for UK patients and members of the public

PIL - Methotrexate 25mg/ml Solution for Injection: Change history

  • 1. To update sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.3 of the

    SmPC and the PIL to be in-line with the product Information of

    reference product Methotrexate 50mg/ 2ml Injection with

    national procedure number: PA0822/206/002 & MAH: Pfizer

    Ireland Limited.

    2. To update sections 4.4 and 4.5 in SmPC and section 2 in

    leaflet information in-line with the product Information of

    reference product (Methotrexate 50mg/ 2ml Injection with

    national procedure number: PA0822/206/002 & MAH: Pfizer

    Ireland Limited).

    3. To update sections 5.1 and 5.2 in SmPC in-line with the

    product Information of reference product (Methotrexate 50mg/

    2ml Injection with national procedure number: PA0822/206/002

    & MAH: Pfizer Ireland Limited).

    PIL sections updated: Sections: 2, 4, 6 and HCP section.

    • Changes: (Updated: 31 Mar 2025)

      1. To update sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.3 of the

      SmPC and the PIL to be in-line with the product Information of

      reference product Methotrexate 50mg/ 2ml Injection with

      national procedure number: PA0822/206/002 & MAH: Pfizer

      Ireland Limited.

      2. To update sections 4.4 and 4.5 in SmPC and section 2 in

      leaflet information in-line with the product Information of

      reference product (Methotrexate 50mg/ 2ml Injection with

      national procedure number: PA0822/206/002 & MAH: Pfizer

      Ireland Limited).

      3. To update sections 5.1 and 5.2 in SmPC in-line with the

      product Information of reference product (Methotrexate 50mg/

      2ml Injection with national procedure number: PA0822/206/002

      & MAH: Pfizer Ireland Limited).

      PIL sections updated: Sections: 2, 4, 6 and HCP section.

    • Changes: (Updated: 07 Jan 2025)

      To update sections 4.4, 4.6, 4.8 & 5.1 of the SmPC to include photosensitivity as a side effect of methotrexate treatment following advice from MHRA. Consequently sections 2 & 4 of the PIL is also being updated. Additionally, section 6.3 of the SmPC is being updated for PL 20075/0344 only, to align information with the PIL.

    • Changes: (Updated: 26 Oct 2023)

      Description of update: Update to product information in-line with the agreed wording of PSUFU (DE/H/PSUFU/00002014/202110)

      PIL sections updated: 2 and 6.

    • Changes: (Updated: 20 Sep 2022)

      Linked to amended product entry

    • Changes: (Updated: 15 Sep 2022)

      Added document ID

    • Changes: (Updated: 12 Sep 2022)

      Initial upload

    View product information as a: